/ /

  • linkedin
  • Increase Font
  • Sharebar

    ECP in refractory glaucoma yields versatility, favorable safety profile with positive results

    Endoscopic view provides multiple potential applications for anterior, posterior segment surgery

    Take-home message: Endoscopic cyclophotocoagulation with vitrectomy and pars plana treatment is effective in reducing IOP in patients with ultra-refractory glaucoma, reducing the need for medications and being relatively well tolerated by patients.

     

    Los Angeles—When it comes to glaucoma that is refractory to multiple aqueous shunts and maximal medical therapy, there is no consensus on its treatment.

    Additional tube shunts present risks of strabismus and tube or plate exposure and discomfort.1 Inflammation, hypotony, and phthisis are all complications associated with transscleral cyclophotocoagulation and cyclocryotherapy.2,3

    I have found success with endoscopic cyclophotocoagulation (ECP) and a procedure, which is ECP with vitrectomy and pars plana treatment (ECP Plus).

    ECP is unique among surgical glaucoma therapies in that it addresses aqueous production rather than aqueous outflow. This gives it the advantage of being effective as a stand-alone procedure or in conjunction with any other procedure that addresses aqueous outflow.

    In addition, ECP is versatile enough to treat open-angle and chronic angle-closure glaucoma, as well as every stage of disease.

    In standard anterior ECP, the anterior ciliary processes are photocoagulated via a clear corneal approach. To get the maximum effect, I recommend treating each process, as much of the process as possible, and in between each process. This should be performed for a complete 360°. Laser power should be titrated so that each process is visibly whitening and shrinking, but not popping.

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results